Enasidenib
Item No. 21277

CAS Registry No.: 1446502-11-9
Formal Name: 2-methyl-1-[[4-[[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-2-propanol
Synonyms: AG-221, CC-90007
MF: C₁₉H₁₇F₆N₇O
FW: 473.4
Purity: ≥98%
UV/Vis.: λmax: 237, 272 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly

Laboratory Procedures

Enasidenib is supplied as a crystalline solid. A stock solution may be made by dissolving the enasidenib in the solvent of choice. Enasidenib is soluble in the organic solvent DMSO, which should be purged with an inert gas, at a concentration of approximately 10 mM.

Description

Enasidenib is an orally available, allosteric inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). It displays selectivity for mutant IDH2 over wild-type IDH2, wild-type IDH1, mutant IDH1, and a panel of kinases. Studies in primary human mutant IDH2-positive acute myeloid leukemia (AML) cells ex vivo and xenograft mouse models have shown that enasidenib can reduce 2-hydroxyglutarate levels, reverse histone and DNA hypermethylation, and promote cellular differentiation. In clinical trials, it has been shown to induce hematological responses in patients with mutant IDH2 AML.

References